Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Potential Mechanism of Exercise Impairment in OSA

3 janvier 2018 mis à jour par: Robert L. Owens, University of California, San Diego

Pulmonary Vasoreactivity as a Potential Mechanism of Exercise Impairment in Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is a common disorder with major cardiovascular sequelae. A recent study confirmed that OSA is associated with impaired exercise capacity and increasing OSA severity predicts worsening exercise capacity, which is a marker of potential increased cardiovascular risk. However, potential mechanisms of decreased exercise capacity caused by OSA remain unclear. Several pathophysiologic mechanisms of OSA have been proposed and investigators hypothesize that endothelial dysfunction leading to exercise-induced right ventricular dysfunction and associated pulmonary hypertension is the potential mechanism for impaired exercise capacity in OSA.

Aperçu de l'étude

Statut

Complété

Description détaillée

Obstructive sleep apnea (OSA) is a common disorder with major cardiovascular sequelae, including increased systemic hypertension and strokes. OSA is highly prevalent among patients with cardiovascular disease (CVD), but OSA remains under-diagnosed, thus under-treated. Furthermore, a recent study confirmed that OSA is associated with impaired exercise capacity and increasing OSA severity predicts worsening exercise capacity, which is a marker of potential increased cardiovascular risk. However, potential mechanisms of decreased exercise capacity caused by OSA remain unclear.

Several pathophysiologic mechanisms of OSA have been proposed to explain this observation. Endothelial dysfunction is one mechanism that may result from OSA-related intermittent hypoxemia, heightened sympathetic activation, and increased blood pressure. Endothelial dysfunction is characterized by alteration of normal endothelial physiology consisting of a reduction in the bioavailability of vasodilators such as nitric oxide leading to impaired endothelium-depended vasodilation. Endothelial dysfunction has been consistently associated with an increased incidence of CVD. Recent evidence also suggests a correlation between endothelial function and exercise capacity.

In addition, endothelial dysfunction of pulmonary vasculature play an integral role in the pathogenesis of pulmonary hypertension (PH), which is defined by a mean pulmonary artery pressure exceeding 25 mm Hg. PH is associated with increased mortality and multiple morbidities including impaired exercise capacity. OSA has been formally recognized as a cause of PH by the World Health Organization (WHO) and the estimated prevalence of PH in patients with OSA is 17%. Repetitive nocturnal hypoxemia, increased sympathetic tone, and diminished endothelial dependent vaso-reactivity contribute to pulmonary artery hypoxic vasoconstriction, subsequently leading to pulmonary vasculature remodeling and PH. Recently, PH induced by exercise was described as part of the PH spectrum and may represent early, mild, PH that is still clinically relevant in many patients. To detect early PH in OSA patients may signify the importance of treatment and compliance for newly diagnosed OSA patients.

In summary, our hypothesis is that OSA patients may have endothelial dysfunction that leads to impaired exercise capacity via exercise-induced pulmonary hypertension. If our hypothesis is correct, non-invasive measurements of endothelial function could be used clinically to risk stratify patients or follow response to treatment.

Type d'étude

Observationnel

Inscription (Réel)

29

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • California
      • San Diego, California, États-Unis, 92093
        • University of California, San Diego

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

30 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Investigators will enroll 30 subjects with OSA (OSA group) and 30 subjects without OSA (control group). The detailed inclusion and exclusion criteria for subjects are listed below. Female subjects will be offered a urinary pregnancy test and only those documented to be non-pregnant will be studied.

La description

Inclusion Criteria:

  • BMI < 30
  • OSA group: diagnosis of untreated moderate-to-severe OSA (apnea-hypopnea index (AHI) ≥ 15 events/h).
  • Control group: no OSA (AHI < 5 events/h).

Exclusion Criteria:

  • Currently using Continuous Positive Airway Pressure (CPAP) or oral appliance treatment for OSA
  • Uncontrolled cardiac co-morbidity, e.g. ischemic heart disease, heart failure, or valvular heart disease that would prevent exercise
  • Uncontrolled pulmonary co-morbidity, e.g. asthma or chronic obstructive pulmonary disease (COPD)
  • Comorbidities that may severely impair peripheral circulation, e.g. uncontrolled diabetes mellitus, or systemic scleroderma
  • Neurological conditions limiting the ability to perform walking or cycling
  • Orthopedic condition limiting the ability to perform walking or cycling
  • Current smokers, alcohol (> 3 oz/day) or use of illicit drugs.
  • Psychiatric disorder, other than mild and controlled depression; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders.
  • Pregnancy

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
OSA Group
Apnea-hypopnea index (AHI) ≥ 15 events/h
Control Group
Apnea-hypopnea index (AHI) < 5 events/h

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Endothelial function, as measured by endoPAT, between OSA patients and matched healthy controls
Délai: Baseline
EndoPAT is a non-invasive measurement of endothelial function, using peripheral arterial tonometry. Exercise tolerance is measured by Cardiopulmonary exercise testing (CPET). Effects of OSA on exercise tolerance and endothelial function will be evaluated.
Baseline

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Right ventricular systolic pressure (RVSP) in response to exercise
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Pulmonary systolic pressure (PASP) in response to exercise
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Right ventricular outflow track (RVOT) peak velocity in response to exercise
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Velocity time interval (VTI) in response to exercise
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Pulmonary artery acceleration time in response to exercise
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Systolic peak tricuspid myocardial annular velocity
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Diastolic peak tricuspid myocardial annular velocity
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Peak tricuspid myocardial annular velocity during isovolumic contraction
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Peak tricuspid myocardial annular velocity during isovolumic relaxation
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Right ventricular (RV) wall stress
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
3-D right ventricular ejection fraction (3D-RVEF)
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Systolic peak right ventricular (RV) strain
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Early diastolic peak right ventricular (RV) strain
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Late diastolic peak right ventricular (RV) strain
Délai: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 juillet 2015

Achèvement primaire (Réel)

9 mai 2017

Achèvement de l'étude (Réel)

9 mai 2017

Dates d'inscription aux études

Première soumission

12 juillet 2015

Première soumission répondant aux critères de contrôle qualité

20 juillet 2015

Première publication (Estimation)

22 juillet 2015

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 janvier 2018

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 janvier 2018

Dernière vérification

1 janvier 2018

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Apnée obstructive du sommeil

3
S'abonner